Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for STK39 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | STK39 (SPAK) Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Active kinase domain available. |
View STK39 Products |
| Gene Delivery | STK39 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and signaling pathway validation. |
View STK39 Products |
| Benchmark Ab | Anti-STK39 Recombinant Antibody High-affinity positive control for Western Blot, IP, and IHC validation. |
View STK39 Products |
| Validator | STK39 siRNA Set Target-specific knockdown pool for functional assay verification. |
View STK39 Products |
| Related Target A | WNK1 Upstream regulator in the WNK-SPAK pathway; essential for hypertension and electrolyte balance assays. |
View WNK1 Products |
| Related Target B | OSR1 Closely related homolog of STK39; critical for selectivity and off-target screening panels. |
View OSR1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity (STK39 vs. OSR1) | Highly purified recombinant OSR1 and STK39 proteins verified by Mass Spectrometry. |
| WNK-Binding Disruption Assays | C-terminal CCT domain truncations of STK39 designed with precise theoretical MW and high purity. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and validated siRNA included |
| Conformational Stability | E. coli or Insect expression systems optimized for structural integrity and batch-to-batch consistency. |
Live STK39 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for STK39 therapeutics is intensifying, with major players shifting focus from traditional systemic vasodilators to targeted small-molecule inhibitors of the WNK-SPAK pathway. As first-generation kinase inhibitors reach the clinic, the next wave of R&D is targeting the unique C-terminal conserved (CCT) domain of STK39 to achieve isoform-specific inhibition without off-target cardiotoxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Kinase Inhibitor) | Academic Consortia, Novartis | Essential Hypertension, Stroke | Enzymatic Assay (Need high-purity active STK39 kinase domain) |
| Small Molecule (Allosteric/CCT) | Biotech Startups | Gitelman Syndrome, Keloid Scars | Binding Affinity Assay (Need sequence-verified C-terminal constructs) |
| siRNA / Gene Therapy | Alnylam, Arrowhead | Refractory Hypertension | In vitro knockdown verification (Need validated siRNA/Lentivirus) |